MaxCyte Other Operating Expenses from 2010 to 2024
| MXCT Stock | USD 3.55 0.03 0.85% |
Other Operating Expenses | First Reported 2010-12-31 | Previous Quarter 89.6 M | Current Value 94.1 M | Quarterly Volatility 30.6 M |
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.4 M, Interest Expense of 138.6 K or Selling General Administrative of 31.6 M, as well as many indicators such as Price To Sales Ratio of 11.17, Dividend Yield of 0.0 or PTB Ratio of 2.2. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
MaxCyte | Other Operating Expenses |
Latest MaxCyte's Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of MaxCyte over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of MaxCyte. It is also known as MaxCyte overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. MaxCyte's Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
MaxCyte Other Operating Expenses Regression Statistics
| Arithmetic Mean | 32,610,203 | |
| Geometric Mean | 21,189,869 | |
| Coefficient Of Variation | 93.75 | |
| Mean Deviation | 24,395,084 | |
| Median | 23,276,700 | |
| Standard Deviation | 30,570,826 | |
| Sample Variance | 934.6T | |
| Range | 87M | |
| R-Value | 0.91 | |
| Mean Square Error | 165.1T | |
| R-Squared | 0.84 | |
| Slope | 6,250,095 | |
| Total Sum of Squares | 13084.1T |
MaxCyte Other Operating Expenses History
About MaxCyte Financial Statements
MaxCyte shareholders use historical fundamental indicators, such as Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 89.6 M | 94.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.